Pentosan Polysulfate Sodium
Class: Interstitial cystitis agent
- Capsules 100 mg
Unknown. Adheres to and may protect the mucosal membrane of the bladder.
Absorption is approximately 3% of dose.
Distributed to the uroepithelium of the GU tract with lesser amounts in liver, spleen, lung, skin, periosteum, and bone marrow. Erythrocyte penetration is low.
68% of dose undergoes desulfation in liver and spleen 1 h after IV administration; partial depolymerization occurs in the kidney.
Renal excretion is 3% as unchanged drug. The t ½ is 24 h (IV) and 4.8 h (oral).
Indications and Usage
For relief of bladder pain or discomfort associated with interstitial cystitis.
Dosage and AdministrationAdults
PO 100 mg 3 times daily.
Store at room temperature (68° to 77°F) in tightly closed container.
Drug InteractionsAnticoagulants, antiplatelet agents, thrombolytics
Pentosan has weak anticoagulant properties and may potentiate the pharmacological action of other anticoagulants, antiplatelet, or thrombolytic drugs.
Laboratory Test Interactions
Headache; emotional lability; depression; dizziness.
Nausea; abdominal pain; diarrhea; dyspepsia.
Liver function abnormalities.
Category B .
Safety and efficacy not established.
Since drug has weak anticoagulant effects, carefully evaluate patients with diseases such as aneurysms, thrombocytopenia, hemophilia, GI ulcerations, polyps, or diverticula before initiating therapy.
Hepatic/Splenic function impairment
Use with caution.
Use with caution in patients with a history of heparin-induced thrombocytopenia.
Unknown. Based on its pharmacology, overdose is likely to manifest as an increased risk of anticoagulation, thrombocytopenia, gastric pain, and liver function abnormalities.
- Instruct patient to take as prescribed and not more frequently than directed.
- Instruct patient to take pentosan polysulfate sodium at least 1 h before or 2 h after meals with a full glass of water.
- Inform patient of possible adverse reactions with other drugs or foods they may be taking.
- Advise patient to consult with health care provider before taking any other medications including OTCs.
- Instruct patient to assess pain relief or improvement and report to the primary care provider at least every 3 mo to determine effectiveness of treatment.
- Instruct patient to be aware of adverse effects such as bleeding complications (eg, ecchymosis, epistaxis, gum hemorrhage) and alopecia areata. Inform health care provider if noted.
- Instruct patient to inform health care provider if needing invasive dental work, surgery, or other procedures that might expose patient to increased risk for bleeding.
- Advise the patient to notify primary caregiver if experiencing jaundice or other signs of liver disease.
Copyright © 2009 Wolters Kluwer Health.
More Pentosan Polysulfate Sodium resources
- Pentosan Polysulfate Sodium Monograph (AHFS DI)
- pentosan polysulfate sodium Concise Consumer Information (Cerner Multum)
- pentosan polysulfate sodium Advanced Consumer (Micromedex) - Includes Dosage Information
- Elmiron Prescribing Information (FDA)
- Elmiron MedFacts Consumer Leaflet (Wolters Kluwer)